B2M and cancer: In some cancers, immunohistochemical evidence suggests that absence of functional (β2-M-associated) HLA class I molecules may be due to a mutational loss of β2-M (29); and in other cancers, a decreased level or the loss of β2-M in tumor cells was found due to the loss of the β2-M locus, or promoter methylation (30,31).